Affinage

TRIM22

E3 ubiquitin-protein ligase TRIM22 · UniProt Q8IYM9

Length
498 aa
Mass
56.9 kDa
Annotated
2026-06-10
100 papers in source corpus 51 papers cited in narrative 51 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 9/9 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

TRIM22 is an interferon- and p53-inducible RING-type E3 ubiquitin ligase that acts as a broad antiviral restriction factor and, in non-viral settings, as a regulator of NF-κB, MAPK/AKT, and autophagy signaling (PMID:15064739, PMID:18656448, PMID:32814880). As an E3 ligase it self-ubiquitylates in vitro with the E2 UbcH5B through its RING domain and is itself degraded by the proteasome (PMID:18656448). Against viruses it engages diverse viral proteins—typically via its C-terminal SPRY/B30.2 domain—and targets them for RING-dependent ubiquitination and proteasomal degradation, including influenza A NP (PMID:23408607), Zika NS1/NS3 (PMID:36042495), and SARS-CoV-2 NSP8 (K48-linked at Lys97) (PMID:38275298), while disrupting trafficking of HIV-1 Gag (PMID:18389079) and ubiquitinating the picornaviral 3C protease and HCV NS5A (PMID:19218198, PMID:25683609). TRIM22 also restricts viruses through ligase-independent mechanisms: it silences the HIV-1 LTR by blocking Sp1 occupancy of the promoter (PMID:21345949, PMID:26683615), maintains HIV-1 proviral latency (PMID:31136823), and deposits heterochromatin on HSV-1 immediate-early promoters (PMID:33524065). It additionally amplifies innate signaling by catalyzing K63-linked polyubiquitination of MAVS to drive TBK1/IRF3/IFN-β output (PMID:40162781). In cancer and other non-viral contexts TRIM22 ubiquitinates numerous substrates—NRF2, IκBα, PHLPP2, Raf-1, CCS, β-Catenin—to modulate antioxidant, NF-κB, MAPK, AKT-p53-p21, and senescence programs (PMID:35636015, PMID:32814880, PMID:38199981, PMID:37258577, PMID:39127340, PMID:39978715). Beyond its catalytic activity, TRIM22 serves as an E3-independent scaffold that promotes autophagosome–lysosome fusion by bridging GABARAP-family proteins to PLEKHM1 and nucleates autophagy initiation by assembling ULK1/ATG13/FIP200 and Beclin-1 PI3K complexes through distinct domains (PMID:38009729, PMID:40337095). TRIM22 variants are linked to very-early-onset inflammatory bowel disease through disrupted NOD2-dependent signaling (PMID:26836588) and to a familial Alzheimer disease phenotype through impaired autophagic clearance (PMID:38009729). Its own expression is controlled at the promoter by IRF-1 (with BRG1 and p300), p53, progesterone receptor, HOXC8, and ELF3, and is suppressed by HBV via 5'-UTR CpG methylation (PMID:21683060, PMID:23670564, PMID:15064739, PMID:26316153, PMID:41265630, PMID:40162781, PMID:28341749).

Mechanistic history

Synthesis pass · year-by-year structured walk · 17 steps
  1. 2004 High

    Established TRIM22 as a directly transcriptionally regulated effector, placing it downstream of the p53 tumor-suppressor network and connecting it to growth control.

    Evidence cDNA microarray, EMSA, and reporter assays identifying a functional p53-response element in intron 1, with a clonogenic growth assay in leukemic cells

    PMID:15064739

    Open questions at the time
    • Did not define the ubiquitin-ligase substrates mediating growth suppression
    • p73 contribution to physiological regulation unresolved
  2. 2008 High

    Defined TRIM22 as a bona fide RING-dependent antiviral restriction factor and an active E3 ligase, answering whether its catalytic domain underlies function.

    Evidence VLP budding and Gag localization assays with RING C15A/C18A mutants for HIV-1; in vitro reconstitution with UbcH5B and in vivo self-ubiquitylation for ligase activity

    PMID:18389079 PMID:18656448

    Open questions at the time
    • Direct ubiquitin substrate for HIV Gag trafficking disruption not pinned down
    • Whether self-ubiquitylation regulates antiviral output unclear
  3. 2009 Medium

    Showed that the SPRY/B30.2 domain and subcellular targeting determine TRIM22 behavior, with species-specific localization and constitutive centrosomal positioning.

    Evidence Domain-swap and VL1/VL3 mutational imaging across human/rhesus TRIM22; immunofluorescence of endogenous protein at centrosomes with microtubule depolymerization

    PMID:19212762 PMID:20006605

    Open questions at the time
    • Functional consequence of centrosomal localization not demonstrated
    • Link between localization and antiviral specificity unestablished
  4. 2009 High

    Demonstrated that TRIM22 antiviral activity against ECMV requires E3 ligase function and direct engagement of a viral substrate, generalizing the degradation model beyond HIV.

    Evidence Antiviral protection assay, Co-IP with 3C protease, ubiquitination assay, and RING deletion in HeLa cells

    PMID:19218198

    Open questions at the time
    • Ubiquitin chain linkage on 3C^PRO not characterized
    • Domain mediating 3C^PRO recognition not mapped
  5. 2011 High

    Separated TRIM22's transcriptional silencing of the HIV-1 LTR from its catalytic activity, revealing a ligase-independent mode of antiviral action.

    Evidence Stable KD and transduction across cell systems, LTR-luciferase reporters with NF-κB site deletions, and E3-dead RING mutant analysis

    PMID:21345949

    Open questions at the time
    • Mechanism of transcriptional repression not yet identified at this stage
    • Nuclear cofactors unknown
  6. 2011 Medium

    Identified upstream control of TRIM22 expression, showing chromatin remodeling is required for IFN-γ-driven induction via IRF-1.

    Evidence BRG1-deficient cells with reconstitution, ChIP of IRF-1 at the TRIM22 promoter, and BRG1 ATPase-domain mutants

    PMID:21683060

    Open questions at the time
    • Whether BRG1 acts directly or via accessory remodelers unresolved
    • Single isogenic cell-line system
  7. 2011 Medium

    Implicated TRIM22 as a positive regulator of NF-κB and inflammatory cytokine output, opening a non-antiviral signaling role.

    Evidence NF-κB luciferase reporter, EMSA, domain deletion mutants, and cytokine ELISA in U937 macrophages

    PMID:21651891

    Open questions at the time
    • Direct molecular target in the NF-κB pathway not identified here
    • Single study
  8. 2013 Medium

    Extended the substrate-degradation model to influenza A NP and revealed context-dependent NF-κB roles via TAB2 degradation.

    Evidence Co-IP, ubiquitination and proteasome-rescue assays for NP in MDCK cells; Co-IP and degradation of TAB2 with RING mutant for TRAF6/NF-κB

    PMID:23408607 PMID:23818111

    Open questions at the time
    • Reconciliation of NF-κB activation versus TAB2-mediated inhibition not addressed
    • Ubiquitin linkage types not all defined
  9. 2015 High

    Mechanistically resolved LTR silencing as blockade of Sp1 promoter binding and broadened restriction to HCV NS5A.

    Evidence Sp1-site reporter deletions, protein-DNA pulldown and ChIP for Sp1 displacement; NS5A ubiquitination and replication assays with TRIM22 KD/OE in Huh-7

    PMID:25683609 PMID:26683615

    Open questions at the time
    • How nuclear TRIM22 is recruited to the LTR without binding Sp1 unresolved
    • NS5A ubiquitination linkage and degradation route not fully defined
  10. 2015 Medium

    Diversified TRIM22 signaling roles to noncanonical NF-κB activation, translational repression, and autophagosomal turnover of a transcription factor.

    Evidence Co-IP and p100/p52 processing with IKKα; eIF4E/eIF4G competition and translation assays; FoxO4 lysosomal degradation with IFN-β reporter and apoptosis assays

    PMID:22509910 PMID:25510414 PMID:26237181

    Open questions at the time
    • Whether these activities operate in the same cell types simultaneously unclear
    • Several rely on single-lab indirect readouts
  11. 2016 Medium

    Connected TRIM22 to human disease, showing patient variants disrupt NOD2-dependent IFN-β and NF-κB signaling in very-early-onset IBD.

    Evidence Whole-exome sequencing with functional studies in patient cells showing impaired NOD2/IFN-β/NF-κB signaling

    PMID:26836588

    Open questions at the time
    • Direct biochemical mechanism linking TRIM22 to NOD2 not defined
    • Single report
  12. 2017 High

    Revealed promoter-level immune evasion and pro-apoptotic functions, defining how viral and host factors tune TRIM22 abundance and outputs.

    Evidence Bisulfite sequencing and IRF-1 binding for HBx-driven CpG methylation in mouse and primary hepatocytes; domain-mutant apoptosis and Bak oligomerization assays in monocytes

    PMID:28079123 PMID:28341749

    Open questions at the time
    • Mechanism by which TRIM22 promotes Bak oligomerization not biochemically defined
    • Generality of single-CpG control across tissues unknown
  13. 2020 High

    Established TRIM22 as an oncogenic NF-κB driver in glioblastoma through dual K48/K63 ubiquitination events, demonstrating in vivo relevance.

    Evidence Reciprocal Co-IP, linkage-specific ubiquitination of IκBα and IKKγ-complex, RING mutant, NF-κB reporter, and orthotopic xenograft

    PMID:32814880

    Open questions at the time
    • Reconciliation with reports of TRIM22 inhibiting NF-κB via TAB2 unresolved
    • Tissue determinants of pro- versus anti-NF-κB activity unknown
  14. 2022 High

    Expanded the substrate repertoire to redox and senescence regulators (NRF2, PHLPP2) and an additional flavivirus restriction (ZIKV), refining domain-specific recognition and catalysis.

    Evidence Co-IP, ubiquitination and E3-mutant assays plus rescue/in vivo for NRF2 and PHLPP2; SPRY-binding/RING-degradation mapping for ZIKV NS1/NS3 with KO infectivity

    PMID:35636015 PMID:36042495 PMID:38199981

    Open questions at the time
    • NRF2 ubiquitination linkage type not fully specified
    • Why some substrates require prior phosphorylation for SPRY recognition unclear
  15. 2023 High

    Defined TRIM22 as an E3-independent autophagy scaffold and extended MAPK-driven oncogenesis, with a familial Alzheimer variant impairing autophagic clearance.

    Evidence Co-IP, PLA, and autophagy-flux assays with E3-dead mutant for GABARAP-PLEKHM1 bridging; Co-IP with domain mapping and xenograft for Raf-1 degradation/MAPK in GBM

    PMID:37258577 PMID:38009729

    Open questions at the time
    • How the scaffolding and ligase activities are coordinated in cells unresolved
    • Raf-1 study is single-lab Medium-confidence
  16. 2024 High

    Broadened catalytic versatility to non-canonical linkages and additional substrates, showing K48 (NSP8), K27 (CCS), and stabilizing non-K48 ubiquitination (Bcl-2) tied to distinct outcomes.

    Evidence Site-specific ubiquitination mutants (NSP8 K97, CCS K76) with domain mapping and functional readouts; ubiquitination microarray and Co-IP for Bcl-2 stabilization

    PMID:38275298 PMID:39127340 PMID:40552115

    Open questions at the time
    • Determinants selecting different chain linkages on different substrates unknown
    • Bcl-2 stabilization mechanism is single-lab Medium-confidence
  17. 2025 High

    Integrated TRIM22 into the RIG-I/MAVS innate signaling axis as a K63-MAVS ubiquitin ligase, and fully delineated its multidomain autophagy-initiation scaffold function.

    Evidence K63-specific MAVS ubiquitination with KO/IFN-β reporters and ELF3 promoter ChIP; domain-deletion Co-IP and competitive-binding autophagy-flux assays for ULK1/ATG13/FIP200/Beclin-1 assembly

    PMID:40162781 PMID:40337095

    Open questions at the time
    • Spatial/temporal switch between MAVS amplification and substrate degradation unresolved
    • Whether scaffold and ligase domains act on overlapping complexes in vivo unclear

Open questions

Synthesis pass · forward-looking unresolved questions
  • It remains unresolved what governs TRIM22's context-dependent choice among catalytic versus scaffold modes, ubiquitin-chain linkage selection, and opposing pro- versus anti-tumorigenic and pro- versus anti-NF-κB outcomes across tissues.
  • No unifying structural model linking domain architecture to mode selection
  • Conflicting NF-κB and oncogenic/tumor-suppressive roles not mechanistically reconciled
  • In vivo physiological substrate hierarchy unknown

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0016740 transferase activity 8 GO:0140096 catalytic activity, acting on a protein 7 GO:0016874 ligase activity 5 GO:0098772 molecular function regulator activity 3 GO:0140110 transcription regulator activity 3 GO:0060090 molecular adaptor activity 2
Localization
GO:0005634 nucleus 3 GO:0005815 microtubule organizing center 1
Pathway
R-HSA-392499 Metabolism of proteins 6 R-HSA-168256 Immune System 5 R-HSA-162582 Signal Transduction 4 R-HSA-9612973 Autophagy 3 R-HSA-1643685 Disease 2
Partners
ATG13BECLIN-1GABARAPIKKGAMMAMAVSPHLPP2PLEKHM1RAF-1
Complex memberships
ULK1-ATG13-FIP200-ATG101 autophagy initiation complexclass III PI3K (Beclin-1) complex

Evidence

Reading pass · 51 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2008 TRIM22 inhibits HIV-1 particle release by targeting HIV Gag, disrupting its trafficking to the plasma membrane; the RING domain catalytic residues Cys15 and Cys18 are required for this antiviral activity. TRIM22 does not block MLV or EIAV Gag particle release, indicating specificity for HIV Gag. RNAi knockdown, overexpression, virus-like particle budding assay, mutational analysis of RING domain (C15A/C18A), fluorescence microscopy of Gag localization PLoS pathogens High 18389079
2008 TRIM22 is a functional E3 ubiquitin ligase that catalyzes self-ubiquitylation in vitro in combination with E2 enzyme UbcH5B, dependent on its RING finger domain; TRIM22 also undergoes self-ubiquitylation in vivo and is targeted for proteasomal degradation via poly-ubiquitin chains. TRIM22 localizes to the nucleus. In vitro ubiquitylation assay with UbcH5B, in vivo ubiquitylation in 293T cells, proteasome inhibitor stabilization assay, subcellular fractionation/localization Biochemical and biophysical research communications High 18656448
2009 TRIM22 E3 ubiquitin ligase activity is required for antiviral protection against encephalomyocarditis virus (ECMV); TRIM22 interacts with the viral 3C protease (3C^PRO) and mediates its ubiquitination. A RING domain deletion mutant abolishes both E3 activity and antiviral effect. Antiviral protection assay in HeLa cells, co-immunoprecipitation of TRIM22 with 3C^PRO, ubiquitination assay, RING deletion mutant analysis The Journal of general virology High 19218198
2011 TRIM22 inhibits HIV-1 LTR-driven transcription independently of its E3 ubiquitin ligase activity, Tat transactivation, and NF-κB binding sites in the LTR. Nuclear TRIM22 suppresses basal and phorbol ester-induced HIV-1 transcription. Stable TRIM22 knockdown in U937 cells, TRIM22 transduction in permissive cells, LTR-luciferase reporter assays with NF-κB site deletion constructs, RING mutant (E3-dead) analysis Journal of virology High 21345949
2013 TRIM22 restricts influenza A virus (IAV) replication by interacting with the viral nucleoprotein (NP) and promoting its polyubiquitination and proteasome-dependent degradation. shRNA knockdown, overexpression in MDCK cells, Co-IP of TRIM22 with NP, ubiquitination assay, proteasome inhibitor rescue, viral titer measurement Journal of virology High 23408607
2011 TRIM22 activates NF-κB in a dose-dependent manner; both the N-terminal RING domain and C-terminal SPRY domain are required for NF-κB activation. TRIM22 overexpression induces pro-inflammatory cytokine secretion in U937 macrophages in an NF-κB-dependent manner. NF-κB luciferase reporter assay, EMSA, domain deletion mutants, cytokine ELISA Biochemical and biophysical research communications Medium 21651891
2015 TRIM22 inhibits HIV-1 LTR-driven transcription by preventing Sp1 binding to the viral promoter; TRIM22 does not interact directly with Sp1 but blocks Sp1 binding as shown by protein-DNA pulldown and chromatin immunoprecipitation. Reporter assays with Sp1-binding-site deletion constructs in 293T cells, TRIM22 KD in SupT1 T cells with HIV replication assay, protein-DNA pulldown, chromatin immunoprecipitation (ChIP) Retrovirology High 26683615
2015 TRIM22 ubiquitinates HCV NS5A protein in a concentration-dependent manner, and TRIM22 expression inhibits HCV replication; siRNA-mediated TRIM22 knockdown diminishes IFNα-induced anti-HCV function. TRIM22 overexpression and siRNA knockdown in Huh-7 cells, HCV replication assay, NS5A ubiquitination assay Cellular & molecular immunology Medium 25683609
2013 TRIM22 inhibits the TRAF6-stimulated NF-κB pathway by interacting with and degrading TAB2 in a RING domain-dependent manner; TRIM22 also decreases TRAF6 self-ubiquitination. NF-κB reporter assay, Co-IP of TRIM22 with TAB2, TAB2 degradation assay with RING deletion mutant, TRAF6 ubiquitination assay Virologica Sinica Medium 23818111
2004 TRIM22 (Staf50) is a direct p53 target gene; a functional p53-response element in intron 1 mediates direct p53 binding (shown by EMSA) and transactivation; p53-family member p73 also transactivates via this element. Ectopic TRIM22 expression reduces clonogenic growth of U937 leukemic cells. cDNA microarray, cycloheximide chase (independence of de novo protein synthesis), EMSA, luciferase reporter assay with intron 1 p53-RE, ectopic expression clonogenic assay Oncogene High 15064739
2009 Human and rhesus TRIM22 localize to different subcellular compartments, and this difference maps to the B30.2/SPRY domain; amino acid changes in variable loops VL1 and VL3 of the B30.2 domain are responsible for the species-specific subcellular localization differences. Fluorescence microscopy of GFP-tagged constructs, domain swap/chimeric protein experiments, mutational analysis of VL1 and VL3 Immunogenetics Medium 19212762
2009 Endogenous TRIM22 colocalizes with centrosomes independently of cell cycle phase in primary human mononuclear cells and U2OS cells, and this colocalization is independent of the microtubule network. Immunofluorescence of endogenous TRIM22 with centrosome markers, microtubule depolymerization experiment, cell cycle staging Experimental cell research Medium 20006605
2012 TRIM22 directly or indirectly interacts with translation initiation factor eIF4E and inhibits eIF4E binding to eIF4G, thereby disrupting eIF4F complex assembly and repressing cap-dependent translation of specific mRNAs including IRF-7C. Co-immunoprecipitation of TRIM22 with eIF4E, eIF4G binding competition assay, luciferase reporter assay, radiolabelled methionine incorporation assay Biology of the cell Medium 22509910
2015 TRIM22 activates the noncanonical NF-κB pathway by interacting with IKKα (but not IKKβ) via its RING and SPRY domains, increasing IKKα levels and phosphorylation, and inducing p100 processing to p52. Co-immunoprecipitation, co-localization, Western blot for p100/p52 processing and IKKα phosphorylation, domain deletion mutants Journal of receptor and signal transduction research Medium 25510414
2016 TRIM22 variants disrupt the ability of TRIM22 to regulate NOD2-dependent activation of IFN-β signaling and NF-κB, establishing TRIM22 as a regulator of the NOD2 signaling pathway in a disease context (very-early-onset IBD). Whole-exome sequencing, functional studies in primary patient cells and cell culture showing disrupted NOD2/IFN-β/NF-κB signaling by TRIM22 variants Gastroenterology Medium 26836588
2020 TRIM22 promotes NF-κB signaling in GBM by: (1) binding IκBα and accelerating its degradation via K48-linked ubiquitination; (2) forming a complex with IKKγ and promoting K63-linked ubiquitination leading to IKKα/β and IκBα phosphorylation. RING domain E3 ligase activity is required for these effects. A non-phosphorylatable IκBα mutant (srIκBα) blocks TRIM22 growth-promoting activity. Co-immunoprecipitation, K48/K63-linked ubiquitination assays, Cas9-sgRNA knockout, RING mutant (C15/18A) and deletion analysis, NF-κB luciferase reporter, orthotopic xenograft model Cell death and differentiation High 32814880
2022 TRIM22 promotes proteasomal degradation of NRF2 via E3 ligase-dependent ubiquitination that is independent of KEAP1, reducing intracellular antioxidant capacity and activating ROS/AMPK/mTOR/autophagy signaling to induce autophagic cell death in osteosarcoma. Co-immunoprecipitation of TRIM22 with NRF2, ubiquitination assay, E3 ligase mutant analysis, ROS measurement, AMPK/mTOR pathway Western blot, in vitro and in vivo gain/loss-of-function with rescue by NRF2 manipulation or NAC/3-MA Redox biology High 35636015
2022 TRIM22 suppresses Zika virus (ZIKV) replication by interacting with viral NS1 and NS3 proteins and promoting their ubiquitination and proteasomal degradation; the SPRY domain mediates protein interaction and the RING domain mediates degradation. TRIM22 also inhibits dengue and yellow fever virus. Co-immunoprecipitation, ubiquitination assay, domain deletion analysis (SPRY and RING), overexpression and TRIM22 KO cell infectivity assay, proteasome inhibitor rescue Cell & bioscience High 36042495
2024 TRIM22 E3 ubiquitin ligase promotes proteasomal degradation of SARS-CoV-2 NSP8 via K48-type ubiquitination at Lys97, thereby restricting viral replication; TRIM22 expression is induced by interferon signaling upon SARS-CoV-2 infection. Co-immunoprecipitation of TRIM22 with NSP8, K48-ubiquitination assay with site-specific Lys97 mutation, TRIM22 overexpression and knockdown viral replication assay mBio High 38275298
2023 TRIM22 induces cellular senescence in hepatocellular carcinoma by targeting PHLPP2 for proteasomal degradation via the SPRY domain binding PHLPP2's C-terminal IKKβ-phosphorylated domain; PHLPP2 degradation activates AKT-p53-p21 signaling leading to senescence. Co-immunoprecipitation with domain mapping, ubiquitination assay, IKKβ phosphorylation analysis, AKT/p53/p21 Western blot, cellular senescence assays (β-galactosidase, SAHF), p53 ChIP for TRIM22 promoter Cell death & disease High 38199981
2023 TRIM22 promotes GBM proliferation by activating MAPK signaling; it binds Raf-1 (a negative regulator) via CC and SPRY domains and accelerates Raf-1 degradation by K48-linked ubiquitination (interaction requires Raf-1 C1D domain). TRIM22 also binds the SPHK2 gene at exon 2 to regulate SPHK2 transcription. Co-immunoprecipitation with domain mapping, K48-ubiquitination assay, ERK1/2 luciferase reporter, TRIM22 KO and OE, RING domain and NLS deletion mutants, in vivo xenograft Experimental & molecular medicine Medium 37258577
2015 TRIM22 ubiquitinates FoxO4 and targets it for degradation via the autophagosomal-lysosomal (not ubiquitin-proteasome) pathway; this antagonizes FoxO4's role in promoting IFN-β expression downstream of TLR3/RIG-I activation. TRIM22 knockdown sensitizes cells to dsRNA-induced caspase-dependent apoptosis and suppresses Bcl-2. TRIM22 KD with poly(I:C) stimulation, FoxO4 KD, IFN-β reporter assay, assessment of FoxO4 protein levels, apoptosis assay (caspase activation), Bcl-2 Western blot Journal of interferon & cytokine research Medium 26237181
2017 HBV X protein (HBx) suppresses TRIM22 transcription through a single CpG methylation in the TRIM22 5'-UTR, which reduces IRF-1 binding affinity to the TRIM22 promoter, thereby enabling HBV to evade innate immune restriction. LC-MS/MS proteomics, bisulfite sequencing for CpG methylation, IRF-1 binding assay, mouse model, primary human hepatocytes Gut High 28341749
2011 BRG1 (chromatin remodeling ATPase) is required for IFN-γ-induced TRIM22 expression; BRG1 deficiency does not impair IFN-γ-induced IRF-1 expression but blocks IRF-1 access to the TRIM22 promoter; BRG1 ATPase domain is required for TRIM22 induction and IRF-1 recruitment. BRG1-deficient SW-13 cell line with BRG1 reconstitution, ChIP of IRF-1 at TRIM22 promoter, BRG1 ATPase domain mutant Biochemical and biophysical research communications Medium 21683060
2013 p300, but not PCAF, functions as a transcriptional co-activator of IRF-1 for IFN-γ-induced TRIM22 expression independently of p300's histone acetyltransferase activity; p300 is required for RNA polymerase II recruitment to the TRIM22 promoter. In vitro DNA affinity binding assay, ChIP of p300 and RNA Pol II at TRIM22 promoter, p300 overexpression and knockdown, HAT-dead p300 mutant European journal of immunology Medium 23670564
2015 TRIM22 is a progesterone-receptor (PR) direct target gene; PR binds a progesterone response element (PRE) in the TRIM22 promoter region (-25 to -11 bp upstream of exon 1) in a hormone-dependent manner, and this PRE has enhancer activity. ChIP of PR at TRIM22 PRE, luciferase reporter assay for PRE activity, PR-stable Ishikawa cell clones, hormone-dependent TRIM22 expression The Journal of steroid biochemistry and molecular biology Medium 26316153
2019 TRIM22 maintains HIV-1 proviral latency in T cell lines; TRIM22 knockdown accelerates reactivation of a dox-controlled HIV-1 in SupT1 cells and potentiates HIV-1 expression in ACH-2 and J-Lat 10.6 cell lines upon TNF-α or HDAC inhibitor stimulation. TRIM22 knockdown in T cell lines, dox-controlled HIV-1 replication system, TNF-α/HDACi stimulation, HIV-1 p24 and luciferase readouts Virus research Medium 31136823
2019 TRIM22 interacts with PRRSV nucleocapsid (N) protein through its SPRY domain; the NLS2 motif of N protein is involved in the interaction with TRIM22. The NLS (nuclear localization signal) and SPRY domain of TRIM22 are both required for inhibition of PRRSV replication; however, PRRSV N protein levels are not altered by TRIM22, whereas N proteins from related arteriviruses (SHFV, EAV, LDV) are reduced by TRIM22 overexpression. Co-IP, TRIM22 domain deletion constructs (ΔSPRY, ΔNLS), ectopic expression and RNAi in MARC-145 cells, viral titer measurement Virus genes Medium 31375995
2021 TRIM22 restricts HSV-1 replication by increasing histone occupancy and heterochromatin on viral immediate-early gene promoters, thereby reducing viral IE gene expression; this represents an epigenetic restriction mechanism independent of ICP0-mediated degradation. TRIM22 KO and overexpression, ChIP for histone occupancy and heterochromatin marks at viral IE promoters, ICP0-null and wild-type virus comparison, viral gene expression analysis PLoS pathogens High 33524065
2023 TRIM22 promotes autophagosome-lysosome fusion by mediating the association of GABARAP family proteins with PLEKHM1, independently of its E3 ubiquitin ligase activity; a TRIM22 variant associated with familial Alzheimer disease interferes with this function and impairs autophagic clearance. Co-IP, proximity ligation assay, TRIM22 KO with autophagy flux assay, E3 ligase-dead mutant analysis, Alzheimer variant functional testing in cells Autophagy High 38009729
2021 TRIM22 promotes PRRSV N protein degradation through the lysosomal pathway by interacting with LC3; PRRSV miR-376b-3p directly targets TRIM22 to impair its anti-PRRSV activity. Co-IP of TRIM22 with PRRSV N protein and LC3, lysosomal pathway inhibitor experiments, miRNA target validation, viral replication assay Journal of virology Medium 34757838
2017 TRIM22 mediates apoptosis in monocytes by promoting Bak expression and oligomerization; both the RING and SPRY domains are required. TRIM22 overexpression activates caspase-9 and caspase-3. TRIM22 overexpression in THP-1 and primary monocytes, domain deletion mutants (ΔRING, ΔSPRY), caspase activation assay, Bak oligomerization analysis by native PAGE/fractionation Scientific reports Medium 28079123
2022 TRIM22 forms a complex with NT5C2 in GBM and differentially regulates RIG-I ubiquitination: TRIM22 promotes K63-linked ubiquitination of RIG-I while NT5C2 promotes K48-linked ubiquitination, regulating the RIG-I/NF-κB/CCAR1 signaling axis. Co-IP, K48/K63-specific ubiquitination assays, TRIM22 KO with RIG-I ubiquitination readout, luciferase reporter, in vivo xenograft Molecular therapy oncolytics Medium 36159777
2024 TRIM22 interacts with PHLPP2 (AKT phosphatase) and induces its proteasomal degradation, leading to AKT activation and cellular senescence via AKT-p53-p21 signaling; IKKβ-mediated phosphorylation of PHLPP2's C-terminal domain is a prerequisite for TRIM22-SPRY-domain-mediated recognition. Co-IP with SPRY domain mapping, ubiquitination assay, IKKβ phosphorylation analysis, AKT/p53/p21 Western blot, β-galactosidase and SAHF senescence assays, TRIM22 KO/OE Cell death & disease High 38199981
2024 TRIM22 ubiquitinates copper chaperone CCS via K27-linked ubiquitination at CCS Lys76, requiring the TRIM22 coiled-coil domain; CCS degradation suppresses STAT3 phosphorylation by increasing ROS, inhibiting breast cancer proliferation and invasion. Label-free proteomics, Co-IP, ubiquitination assay with linkage-specific antibodies, site-directed mutagenesis (K76R of CCS), TRIM22 coiled-coil domain deletion mutant, ChIP-qPCR, ROS measurement, RNA-seq GSEA Cancer letters High 39127340
2024 WTAP promotes m6A modification of TRIM22 5'UTR via the m6A reader IGF2BP1, increasing TRIM22 expression; TRIM22 then interacts with OPA1 and induces its ubiquitination, causing mitochondrial dysfunction in diabetic nephropathy. RNA immunoprecipitation for m6A detection of TRIM22 5'UTR, Co-IP of TRIM22 with OPA1, ubiquitination assay, mitochondrial function assays Redox report Medium 39314036
2025 TRIM22 enhances RIG-I-mediated antiviral signaling by catalyzing K63-linked polyubiquitination of MAVS, activating the TBK1/IRF3 pathway and IFN-β production; TRIM22 also inhibits the MAVS-NLRX1 inhibitory complex assembly. RNA virus infection induces TRIM22 expression via nuclear translocation of transcription factor ELF3, which activates TRIM22 gene transcription. Co-IP, K63-specific ubiquitination assay of MAVS, TRIM22 KO/KD with IFN-β reporter and TBK1/IRF3 phosphorylation assay, ELF3 nuclear translocation and ChIP/reporter assay for TRIM22 promoter, MAVS-NLRX1 Co-IP Journal of virology High 40162781
2025 TRIM22 functions as a scaffold protein for autophagy initiation: SPRY domain mediates interaction with ATG13 and FIP200; N-terminal region interacts with ULK1 and ATG101; B-box domain is required for interaction with Beclin-1 and assembly of the class III PI3K complex; Beclin-1 and PLEKHM1 compete for overlapping TRIM22 binding regions. This function is independent of E3 ubiquitin ligase activity. Co-IP with domain deletion constructs, competitive binding assay, autophagy flux assay (LC3-II, autophagic clearance), TRIM22 KO, mTOR/AMPK activity measurement, primary neuron experiments Animal cells and systems High 40337095
2024 TRIM22 ubiquitinates TCF4 via K48-linked ubiquitination mediated by the TRIM22 RING domain, leading to TCF4 proteasomal degradation and suppression of ovarian cancer cell proliferation and invasion. Co-IP, ubiquitination assay with RING domain deletion mutant, rescue of TRIM22 phenotype by TCF4 overexpression Molecular cancer research Medium 38842601
2025 TRIM22 promotes K63-linked ubiquitination of p21 via its SPRY domain (interaction) and RING domain (catalysis), inducing p21 degradation through the proteasome pathway to accelerate cell cycle progression in melanoma. S-protein pulldown of p21 with TRIM22 SPRY domain, ubiquitination assay (K63-linked), CHX chase confirming proteasomal degradation, p21 KD epistasis experiment Scientific reports Medium 40593126
2025 TRIM22 ubiquitinates and degrades CDT2 (CRL4 subunit), acting as a novel E3 ligase for CDT2 in HPV-positive cervical cancer cells; E6-mediated p53 degradation downregulates TRIM22 (a p53 target), leading to CDT2 accumulation that promotes cancer cell growth and survival. Ubiquitination assay of CDT2 by TRIM22, Western blot and KD/OE for CDT2/TRIM22 relationship, epistasis with E6/E7, p53 transcription of TRIM22 Neoplasia Medium 40680432
2025 TRIM22 interacts with KAT2A and promotes its ubiquitination-dependent degradation in melanoma cells; loss of TRIM22 allows KAT2A accumulation, which binds the Notch1 promoter to increase H3K9ac and activate Notch1 transcription, promoting cancer stemness. Co-IP, ubiquitination assay, ChIP of KAT2A at Notch1 promoter for H3K9ac, TRIM22 KO/OE, Notch1 inhibitor rescue Journal of translational medicine Medium 37415153
2025 HOXC8 transcriptionally activates TRIM22 expression; TRIM22 then ubiquitinates and degrades IκBα, activating NF-κB signaling to drive stemness maintenance in colorectal cancer cells. Luciferase reporter and ChIP for HOXC8-TRIM22 promoter interaction, ubiquitination assay of IκBα by TRIM22, NF-κB activity and stemness markers Cancer letters Medium 41265630
2025 TRIM22 interacts with ADRB2 (β-2 adrenergic receptor) and negatively regulates ADRB2 expression and JAK2/STAT3 signaling in lung adenocarcinoma cells. STRING database prediction, co-immunoprecipitation of TRIM22 with ADRB2, ADRB2 and TRIM22 KD/OE with JAK2/STAT3 Western blot and cell proliferation assay Scientific reports Low 40594822
2021 Constitutive TRIM22 expression in lung/respiratory tract epithelia (independent of IFN stimulation) is sufficient to restrict influenza A virus replication by inhibiting viral transcription onset, representing an intrinsic (pre-existing) defense. Transcriptomic analysis of human tissues, primary respiratory cell lines, rhesus macaque airway TRIM22 expression, TRIM22 KD with IAV replication assay (viral transcript measurement), comparison of IFN-dependent vs constitutive expression Frontiers in cellular and infection microbiology Medium 34621686
2022 TRIM22 negatively regulates MHC class II protein expression through a mechanism other than transcription or protein degradation; TRIM22 KO increases MHC-II protein levels while OE decreases them, without affecting CIITA or MHC-II mRNA levels. Cas9-sgRNA knockout and TRIM22 overexpression, Western blot for MHC-II protein and mRNA (qPCR), cycloheximide chase for MHC-II degradation Biochimica et biophysica acta. Molecular cell research Low 35777501
2025 TRIM22 promotes GBM cell survival by stabilizing Bcl-2 via non-degradative (non-K48) ubiquitination; TRIM22 binds Bcl-2 and increases its protein expression levels. Immunoprecipitation of TRIM22-Bcl-2 complex, ubiquitination microarray, ubiquitination assay, Western blot, flow cytometry apoptosis assay Molecular & cellular oncology Medium 40552115
2024 TRIM22 directly interacts with KAT2A and promotes KAT2A ubiquitination and degradation in hepatocellular carcinoma cells, reducing H3K9ac enrichment at the GPX4 promoter and promoting ferroptosis through the KAT2A/GPX4 axis; O-GlcNAcylation of KAT2A at S583 blocks TRIM22-mediated ubiquitination, stabilizing KAT2A. Co-IP of TRIM22 with KAT2A, ubiquitination assay, ChIP-qPCR for H3K9ac at GPX4 promoter, ferroptosis markers (Fe2+, MDA, ROS, GSH), O-GlcNAcylation site mutant (S583A), in vivo tumor model Histology and histopathology / Cancer science Medium 39698827 42114931
2025 TRIM22 inhibits colorectal cancer metastasis by directly interacting with and ubiquitinating β-Catenin, promoting its degradation and inhibiting EMT; this anti-metastatic effect depends on TRIM22 E3 ligase activity. Co-IP of TRIM22 with β-Catenin, ubiquitination assay, TRIM22 OE/KD with β-Catenin rescue, in vivo metastasis model Experimental cell research Medium 39978715
2022 TRIM22 negatively regulates TLR3-induced CCL5 expression in human renal proximal tubular epithelial cells; TRIM22 is induced downstream of IFN-β in a TLR3-IFN-β-TRIM22 pathway, and its knockdown upregulates poly(I:C)-induced CCL5 production. siRNA knockdown of TRIM22 and IFN-β, poly(I:C) stimulation, TRIM22/CCL5/IFN-β mRNA and protein quantification in hRPTECs Molecular biology reports Medium 40080304
2022 TRIM22 directly interacts with Smad2 in gastric cancer cells; overexpression of TRIM22 downregulates Smad2 phosphorylation and Smad3 phosphorylation; Smad2 overexpression reverses TRIM22-induced inhibition of proliferation and migration. Co-IP of TRIM22 with Smad2, Western blot for p-Smad2/3, rescue experiment with Smad2 overexpression, in vivo xenograft Cell death discovery Medium 34489426

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2008 The interferon response inhibits HIV particle production by induction of TRIM22. PLoS pathogens 232 18389079
2013 TRIM22 inhibits influenza A virus infection by targeting the viral nucleoprotein for degradation. Journal of virology 210 23408607
2022 TRIM22 inhibits osteosarcoma progression through destabilizing NRF2 and thus activation of ROS/AMPK/mTOR/autophagy signaling. Redox biology 151 35636015
2007 Discordant evolution of the adjacent antiretroviral genes TRIM22 and TRIM5 in mammals. PLoS pathogens 142 18159944
2020 TRIM22 activates NF-κB signaling in glioblastoma by accelerating the degradation of IκBα. Cell death and differentiation 129 32814880
2009 TRIM22 E3 ubiquitin ligase activity is required to mediate antiviral activity against encephalomyocarditis virus. The Journal of general virology 104 19218198
2016 Variants in TRIM22 That Affect NOD2 Signaling Are Associated With Very-Early-Onset Inflammatory Bowel Disease. Gastroenterology 97 26836588
2011 TRIM22 inhibits HIV-1 transcription independently of its E3 ubiquitin ligase activity, Tat, and NF-kappaB-responsive long terminal repeat elements. Journal of virology 92 21345949
2015 Interferon alpha (IFNα)-induced TRIM22 interrupts HCV replication by ubiquitinating NS5A. Cellular & molecular immunology 83 25683609
2004 Staf50 is a novel p53 target gene conferring reduced clonogenic growth of leukemic U-937 cells. Oncogene 67 15064739
2010 Association of TRIM22 with the type 1 interferon response and viral control during primary HIV-1 infection. Journal of virology 66 20980524
2017 Suppression of interferon-mediated anti-HBV response by single CpG methylation in the 5'-UTR of TRIM22. Gut 63 28341749
2015 HIV-1 transcriptional silencing caused by TRIM22 inhibition of Sp1 binding to the viral promoter. Retrovirology 63 26683615
2008 Identification of TRIM22 as a RING finger E3 ubiquitin ligase. Biochemical and biophysical research communications 56 18656448
2006 Stimulated trans-acting factor of 50 kDa (Staf50) inhibits HIV-1 replication in human monocyte-derived macrophages. Virology 55 16926043
2011 Identification of tripartite motif-containing 22 (TRIM22) as a novel NF-κB activator. Biochemical and biophysical research communications 50 21651891
2012 TRIM22: A Diverse and Dynamic Antiviral Protein. Molecular biology international 49 22649727
2013 TRIM22 inhibits the TRAF6-stimulated NF-κB pathway by targeting TAB2 for degradation. Virologica Sinica 42 23818111
2021 TRIM22. A Multitasking Antiviral Factor. Cells 37 34440633
2018 TRIM22 knockdown suppresses chronic myeloid leukemia via inhibiting PI3K/Akt/mTOR signaling pathway. Cell biology international 36 29762880
2018 TRIM22 regulates macrophage autophagy and enhances Mycobacterium tuberculosis clearance by targeting the nuclear factor-multiplicity κB/beclin 1 pathway. Journal of cellular biochemistry 36 30011088
2000 The interferon-inducible Staf50 gene is downregulated during T cell costimulation by CD2 and CD28. Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 31 11096452
2024 TRIM22 induces cellular senescence by targeting PHLPP2 in hepatocellular carcinoma. Cell death & disease 30 38199981
2018 The interferon-stimulated gene TRIM22: A double-edged sword in HIV-1 infection. Cytokine & growth factor reviews 30 29650252
2023 TRIM22 promotes the proliferation of glioblastoma cells by activating MAPK signaling and accelerating the degradation of Raf-1. Experimental & molecular medicine 28 37258577
2020 Knockdown of TRIM22 Relieves Oxygen-Glucose Deprivation/Reoxygenation-Induced Apoptosis and Inflammation Through Inhibition of NF-κB/NLRP3 Axis. Cellular and molecular neurobiology 28 32335773
2022 TRIM22 suppresses Zika virus replication by targeting NS1 and NS3 for proteasomal degradation. Cell & bioscience 26 36042495
2019 Nuclear localization signal in TRIM22 is essential for inhibition of type 2 porcine reproductive and respiratory syndrome virus replication in MARC-145 cells. Virus genes 26 31375995
2023 TRIM22 facilitates autophagosome-lysosome fusion by mediating the association of GABARAPs and PLEKHM1. Autophagy 25 38009729
2007 Regulation of the interferon-inducible p53 target gene TRIM22 (Staf50) in human T lymphocyte activation. Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 24 17970695
2021 TRIM22 inhibits the proliferation of gastric cancer cells through the Smad2 protein. Cell death discovery 23 34489426
2022 TRIM22 actives PI3K/Akt/mTOR pathway to promote psoriasis through enhancing cell proliferation and inflammation and inhibiting autophagy. Cutaneous and ocular toxicology 22 36170453
2021 Tripartite Motif 22 (TRIM22) protein restricts herpes simplex virus 1 by epigenetic silencing of viral immediate-early genes. PLoS pathogens 22 33524065
2014 TRIM5α and TRIM22 are differentially regulated according to HIV-1 infection phase and compartment. Journal of virology 22 24478420
2007 Expression of the IFN-inducible p53-target gene TRIM22 is down-regulated during erythroid differentiation of human bone marrow. Leukemia research 22 17257675
2024 The E3 ligase TRIM22 restricts SARS-CoV-2 replication by promoting proteasomal degradation of NSP8. mBio 21 38275298
2021 MicroRNA-376b-3p Promotes Porcine Reproductive and Respiratory Syndrome Virus Replication by Targeting Viral Restriction Factor TRIM22. Journal of virology 21 34757838
2017 TRIM22-Mediated Apoptosis is Associated with Bak Oligomerization in Monocytes. Scientific reports 20 28079123
2024 The E3 ligase TRIM22 functions as a tumor suppressor in breast cancer by targeting CCS for proteasomal degradation to inhibit STAT3 signaling. Cancer letters 19 39127340
2018 miR-215 Enhances HCV Replication by Targeting TRIM22 and Inactivating NF-κB Signaling. Yonsei medical journal 18 29749134
2013 Identification of TRIM22 single nucleotide polymorphisms associated with loss of inhibition of HIV-1 transcription and advanced HIV-1 disease. AIDS (London, England) 18 23921607
2009 Different subcellular localisations of TRIM22 suggest species-specific function. Immunogenetics 18 19212762
2022 FOXC1‑mediated TRIM22 regulates the excessive proliferation and inflammation of fibroblast‑like synoviocytes in rheumatoid arthritis via NF‑κB signaling pathway. Molecular medicine reports 17 35946462
2012 The p53 target gene TRIM22 directly or indirectly interacts with the translation initiation factor eIF4E and inhibits the binding of eIF4E to eIF4G. Biology of the cell 17 22509910
2009 The human IFN-inducible p53 target gene TRIM22 colocalizes with the centrosome independently of cell cycle phase. Experimental cell research 17 20006605
2022 Evolution of TRIM5 and TRIM22 in Bats Reveals a Complex Duplication Process. Viruses 16 35215944
2022 TRIM22 orchestrates the proliferation of GBMs and the benefits of TMZ by coordinating the modification and degradation of RIG-I. Molecular therapy oncolytics 15 36159777
2020 FOXO3/TRIM22 axis abated the antitumor effect of gemcitabine in non-small cell lung cancer via autophagy induction. Translational cancer research 15 35117439
2015 Identification of TRIM22 as a progesterone-responsive gene in Ishikawa endometrial cancer cells. The Journal of steroid biochemistry and molecular biology 15 26316153
2024 WTAP-mediated m6A modification of TRIM22 promotes diabetic nephropathy by inducing mitochondrial dysfunction via ubiquitination of OPA1. Redox report : communications in free radical research 14 39314036
2023 Aberrant KAT2A accumulations render TRIM22-low melanoma sensitive to Notch1 inhibitors via epigenetic reprogramming. Journal of translational medicine 14 37415153
2022 Mechanism of autophagy induced by activation of the AMPK/ERK/mTOR signaling pathway after TRIM22-mediated DENV-2 infection of HUVECs. Virology journal 14 36587218
2020 TRIM22 inhibits respiratory syncytial virus replication by targeting JAK-STAT1/2 signaling. Journal of medical virology 14 32803897
2014 In silico analysis of functional single nucleotide polymorphisms in the human TRIM22 gene. PloS one 14 24983760
2015 TRIM22 can activate the noncanonical NF-κB pathway by affecting IKKα. Journal of receptor and signal transduction research 13 25510414
2013 Induction of TRIM22 by IFN-γ Involves JAK and PC-PLC/PKC, but Not MAPKs and pI3K/Akt/mTOR Pathways. Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 13 23659673
2023 miR-548c-3p targets TRIM22 to attenuate the Peg-IFN-α therapeutic efficacy in HBeAg-positive patients with chronic hepatitis B. Antiviral research 11 37019306
2021 Constitutive TRIM22 Expression in the Respiratory Tract Confers a Pre-Existing Defence Against Influenza A Virus Infection. Frontiers in cellular and infection microbiology 11 34621686
2019 Interferon-inducible TRIM22 contributes to maintenance of HIV-1 proviral latency in T cell lines. Virus research 11 31136823
2015 Control of FoxO4 Activity and Cell Survival by TRIM22 Directs TLR3-Stimulated Cells Toward IFN Type I Gene Induction or Apoptosis. Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 10 26237181
2014 Ancient and recent adaptive evolution in the antiviral TRIM22 gene: identification of a single-nucleotide polymorphism that impacts TRIM22 function. Human mutation 10 24863734
2022 Role of TRIM22 in ulcerative colitis and its underlying mechanisms. Molecular medicine reports 9 35674157
2021 Knockdown of Tripartite motif-containing 22 (TRIM22)relieved the apoptosis of lens epithelial cells by suppressing the expression of TNF receptor-associated factor 6 (TRAF6). Bioengineered 9 34558381
2020 Long Noncoding RNA LINC01207 Promotes Colon Cancer Cell Proliferation and Invasion by Regulating miR-3125/TRIM22 Axis. BioMed research international 9 33299853
2024 SP140 inhibitor suppressing TRIM22 expression regulates glioma progress through PI3K/AKT signaling pathway. Brain and behavior 8 38468469
2024 Ubiquitin Ligase TRIM22 Inhibits Ovarian Cancer Malignancy via TCF4 Degradation. Molecular cancer research : MCR 8 38842601
2013 p300, but not PCAF, collaborates with IRF-1 in stimulating TRIM22 expression independently of its histone acetyltransferase activity. European journal of immunology 8 23670564
2011 BRG1 is indispensable for IFN-γ-induced TRIM22 expression, which is dependent on the recruitment of IRF-1. Biochemical and biophysical research communications 8 21683060
2025 The ELF3-TRIM22-MAVS signaling axis regulates type I interferon and antiviral responses. Journal of virology 7 40162781
2013 Elevated rate of fixation of endogenous retroviral elements in Haplorhini TRIM5 and TRIM22 genomic sequences: impact on transcriptional regulation. PloS one 7 23516500
2022 TRIM22 negatively regulates MHC-II expression. Biochimica et biophysica acta. Molecular cell research 6 35777501
2022 Impact of TRIM5α and TRIM22 Genes Expression on the Clinical Course of Coronavirus Disease 2019. Archives of medical research 6 36621405
2025 IFNβ drives ferroptosis through elevating TRIM22 and promotes the cytotoxicity of RSL3. Frontiers in immunology 5 39975542
2025 Lycorine hydrochloride Suppresses the Proliferation and Invasion of Esophageal Cancer by Targeting TRIM22 and Inhibiting the JAK2/STAT3 and Erk Pathways. Cancers 5 40075566
2025 TRIM22 functions as a scaffold protein for autophagy initiation. Animal cells and systems 5 40337095
2025 E3 ligase TRIM22 promotes melanoma proliferation by regulating cell cycle progression through K63-linked ubiquitination of p21. Scientific reports 5 40593126
2023 A novel TRIM22 gene polymorphism promotes the response to PegIFNα therapy through cytokine-cytokine receptor interaction signaling pathway in chronic hepatitis B. Microbiology spectrum 5 37882560
2020 Expression of TRIM22 mRNA in chronic hepatitis C patients treated with direct-acting antiviral drugs. APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 5 31863490
2025 TRIM22 inhibits the metastasis of colorectal cancer through facilitating β-Catenin degradation. Experimental cell research 4 39978715
2024 Diagnostic value of TRIM22 in diabetic kidney disease and its mechanism. Endocrine 4 39509016
2025 TRIM22 governs tumorigenesis and protects against endometrial cancer-associated cachexia by inhibiting inflammatory response and adipose thermogenic activity. Cancer & metabolism 3 40200303
2025 Knockdown of TRIM22 regulates the expression of NF-κB/NLRP3 and alleviates inflammation and renal injury in mice with lupus nephritis. Allergologia et immunopathologia 3 40342119
2024 Targeted regulation of miR-154-5p/Cullin2 pathway by hsa_circ_TRIM22 in promoting human papillomavirus 16 positive cervical cancer progression. Journal of Cancer 3 38495497
2024 TRIM22 mechanism promoting KAT2A ubiquitination degradation to regulate ferroptosis in hepatocellular carcinoma cell invasion and metastasis. Histology and histopathology 3 39698827
2021 TRIM22 genotype is not associated with markers of disease progression in children with HIV-1 infection. AIDS (London, England) 2 34870928
2025 Tripartite motif 22 (TRIM22) downregulates TLR3-induced CCL5 expression in human renal proximal tubular epithelial cells. Molecular biology reports 1 40080304
2025 ADRB2 is regulated by TRIM22 and facilitates lung adenocarcinoma progression via JAK2/STAT3 signaling pathway. Scientific reports 1 40594822
2025 The TRIM22-CDT2 axis is the key mediator of the p53-Rb signals in growth control of HPV-positive cervical carcinoma cells. Neoplasia (New York, N.Y.) 1 40680432
2025 Research on E3 ubiquitin ligase TRIM22 knockdown regulating macrophage polarization and osteoclast differentiation through the NF-κB/MAPK pathway. Connective tissue research 1 41201163
2025 HOXC8-activated TRIM22/NF-κB pathway promotes stemness in colorectal cancer. Cancer letters 1 41265630
2018 Retracted Article: TRIM22 functions as an oncogene in gliomas through regulating the Wnt/β-catenin signaling pathway. RSC advances 1 35548737
2026 Induction of TRIM22 promotes autophagy and apoptosis of colorectal cancer through reactive oxygen species generation. Journal of translational medicine 0 41668063
2026 Machine learning-driven discovery of STAT1 and TRIM22 as immune biomarkers for lupus nephritis: translational insights into diagnosis and pathogenesis. Scientific reports 0 41714378
2026 PRKCQ-TRIM22 axis promotes proliferation and metastasis of oral squamous cell carcinoma via autophagosome‒lysosome pathway activation. Cancer cell international 0 41764502
2026 O-GlcNAcylation of KAT2A Enhances Bladder Cancer Proliferation by Inhibiting the KAT2A-TRIM22 Interaction. Cancer science 0 42114931
2025 TRIM22 promotes glioblastoma development by ubiquitinating Bcl-2. Molecular & cellular oncology 0 40552115
2025 TRIM22 in Litopenaeus vannamei activates Dorsal by accelerating Cactus's degradation to mediate antiviral immunity. Fish & shellfish immunology 0 40683582
2025 Systematic analysis identifies TRIM22 as an oncogenic and immunological biomarker in glioma. BMC cancer 0 40702424
2025 Induction of TRIM22 during Clonorchis sinensis infection triggers intracellular ROS accumulation by suppressing the mTOR-mediated Nrf2 signaling pathway. Genes & genomics 0 41118115
2015 [Expressions and co-localization of HIV capsid protein p24 and TRIM22 in HEK293T cells]. Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology 0 26271984

Missed literature

Know a paper Affinage missed for TRIM22? Flag it for the maintainers and the community.

No submissions yet.